Long term treatment of HIV-infection with TMC278
USRE50189E1 · kind E1 · reissue
0Cited by
6References
64Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 13, 2021 |
| Grant date | Oct 29, 2024 |
| Priority date | — |
| Expiry date | Sep 13, 2041 |
Classification
- Technology area (CPC —)General
Abstract
This invention relates to the use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for the manufacture of a medicament for the treatment of a subject being infected with HIV, wherein the formulation is to be administered intermittently at a time interval of at least one week.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.